the challenges of glp gfp in context of immunogenecity assays for biologics - med immune...
TRANSCRIPT
![Page 1: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/1.jpg)
Eric GarsonMedImmune, Sir Aaron Klug Building, Granta Park, Cambridge, CB21 6GH
10th March 2017
The Challenges Of GLP/GCP In The Context of
Immunogenicity Assays For Biologics/Biopharmaceuticals
![Page 2: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/2.jpg)
Part 1 : GLP/GCPPart 2 :
ImmunogenicityPart 3 :
Applications
![Page 3: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/3.jpg)
Part 1 : GLP/GCP
![Page 4: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/4.jpg)
GLP & GCP OVERALL• GLP (Good Laboratory Practice) is a set of
principles which ensures non-clinical health studies are planned, performed and monitored, recorded, reported and archived.
• Internationally recognised/accepted set of formal regulations/laws for conducting non-clinical & pre-clinical studies.
• GCP (Good Clinical Practice) applies to clinical studies/phase of drug development.
• GLP applies to pre-clinical drug development in laboratories, animal houses or in the field.
![Page 5: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/5.jpg)
GLP & GCP Objectives Introduced1978 FDA 1982 OECD (Organisation for Economic Co-
Operation). Published Principles of GLP – International
Standards for Mutual Acceptance of Data (MAD). Why:
robust, standardized, reliable, reproducible, safe, accountable, transparent and traceable.
Minimal cost for maximum value/benefit. GLP/GCP Monitored:
Quality Assurance (QA)- internal/external Monitoring Agencies (MA) e.g. FDA, MHRA,
EMA & Chinese FDA. Prevents falsifying evidence & inadequate
control of facilities.
![Page 6: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/6.jpg)
ELEMENTS OF GLP SOPS (Standard Operating
Procedures) Risk Assessments & MSDS Computer systems
Statistical Procedures Regulators have acceptable statistical
procedures Validation of Equipment
Maintained Consistently documented Clean, model & serial number Manufactures operating window &
calibrated equipment. Analyst Training and Education
Certification/qualified, proof of training/competency all must be documented.
Needed for legal purposes.
Updating laboratory records and length of time holding those records.
Adequate Facilities for Studies Space, ventilated, size, hygiene quality
and storage. What category of the laboratory is it fit for
purpose? Animal storage/care. Has it been certified
by an external agency. Who’s responsible? Cleaning rota?
Reagents and Materials Dated? Who made the reagent, expiration date,
concentration, LOT number, deterioration, temperature
range & ambient storage temperature. Tracking of Specimens
Chain of custody - paper/electronic.
![Page 7: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/7.jpg)
ELEMENTS OF GCP Confidentially
Anonymity of Patient data is kept in locked filing cabinet.
Patient consent Patient Information sheet Not coerced into study. Option to leave trial at any time?
Tracking A log/pathway from acquisition
from patient - sample – scan – report
A clear history clear logging each stage beginning to end.
Correct handling of samples and materials Does the sample/vaccine/drug
need to be refrigerated?
![Page 8: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/8.jpg)
CHALLENGES OF GLP & GCP MedImmune is Global
Multiple facilities and multiple studies concurrently.
Different jurisdictions interpret rules differently.
Different sites within the same team might organisation the same rules differently.
Harmonising methodology across oceans is difficult.
Poor communication plays a factor. Impartiality of Monitoring Authorities
(MA) No conflicts of interest. Independence is essential.
New/evolving technology/methodologies GLP/GCP keeping up. Biotech is a completive - balancing pressures
of harmonisation, globalisation & new technology, whilst applying standards.
![Page 9: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/9.jpg)
VIOLATING GLP & GCP Failure to implement
GLP/GCP leads to inquiries, cautions & potentially disqualification of the laboratory, stopping it from practicing. Falsifying evidence,
observations & breaking protocols.
No procedures for calibration & no documentation for training.
Failure to comply with law. Not retaining or submitting
records.
![Page 10: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/10.jpg)
OVERCOMING GLP & GCP CHALLENGES Rule of One – One study
director, one protocol, and one final report. A central monitoring team
for the primary endpoint. A strong relationship
between TF and MA for challenging MA findings if necessary.
GLP/OECD status If a company places a new
study in a country for the first time, know their status.
![Page 11: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/11.jpg)
Part 2 : Immunogenicity
Part 2 : Immunogenicit
y
![Page 12: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/12.jpg)
BIOLOGICALS, BIOLOGICS, BIO-THERAPEUTICS (BTP’S)
Biologics, Bio-therapeutics (BTP’s) or Therapeutic Monoclonal Antibodies - fastest growing field of drug development.
Account for 50% of medicines in the future. First developed in the 1970’s. First approved - Insulin 1982. Today 200+ licensed biologics on market. Biologics/Biologicals encompass proteins, peptides,
gene therapy, & vaccines. Focus monoclonal antibodies. Non-self-antigen proteins provoke an unintended
immune response, this is termed immunogenicity. Development of antibodies against the drug termed
anti-drug antibodies (ADA).
![Page 13: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/13.jpg)
ADA IMPLICATIONS ADA reduces serum levels
Interferes Pharmacodynamics (PD) and Pharmacokinetics (PK). Clears unbound drug.
Affects safety profile - efficacy ADA implications for patient health
Hypersensitivity reactions. Anaphylaxis. Death.
ADA occur in anti-TNF treatments for Rheumatoid Arthritis (RA). There are 5 treatments for RA, including adalimumab and Infliximab.
ADA reduces Infliximab levels – efficacy. mAb’s modified by glycosylation & pegylation lead to increased
immunogenicity. Immunogenicity testing - integral for FDA approval –
FDA Draft Guidance for Inductor on Assay Development for Immunogenicity Testing of Therapeutic Proteins 2009.
Requirements for BTP approval. Need safety profile for licensing
![Page 14: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/14.jpg)
![Page 15: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/15.jpg)
ADA NEUTRALISING ANTIBODIES ADA antibodies include:
Sustaining Clearing Neutralising antibodies
Neutralising antibodies form immune complexes cleared by the immune system.
300kDa sizes or 4000kDa sizes. The larger the complexes more likelier to be
cleared from the immune system. Determined by Genetics.
IgG4 high affinity for epitopes of monoclonal antibodies.
![Page 16: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/16.jpg)
FACTORS AFFECTING IMMUNOGENICITY Drug Extrinsic factors
Method of administration - intravenous least immunogenic. Length of drug treatment Dosage Frequency of administration
Drug Intrinsic factors formulation structure packaging chemical impurities amino acid sequence
Patient factors Genetic profile - MHC alleles can determine an immune response. Immune profile/status
![Page 17: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/17.jpg)
IMMUNOGENICITY ADA ASSAYS Requirements:
ADA Detection - magnitude and neutralising potential. Optimized, robust, specific standardized, meaningful,
validated, accurate & give confidence in data. No magic bullet, need a strategy. Drug interference must be taken into account. ADA are only detectable over a threshold, therefore drug
interference can lead to false negatives. They need cut-off points.
Assays are Qualitative - positive control cannot address heterogeneity in samples.
Test when the drug is eliminated from body. If treatment is for chronic illness, assays must apply for 12
months. Inadequately designed tests can delay or void results.
![Page 18: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/18.jpg)
TYPES OF ADA ASSAYS Direct/Indirect ELISA (Enzyme
Linked Immunosorbent Assay) Inexpensive but high background.
Bridging ELISA Most Used Easy of use High Through-Put
ECL (Enhanced Chemiluminescent) Might miss IgG4
RIA (Radioimmunoprecipitation Assay) Might miss low levels of ADA.
Surface Plasmon Resonance Automated but expensive
Gyrolab system Infliximab
![Page 19: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/19.jpg)
“THE PATIENT IS ALWAYS WAITING” Treatment must stops
if immunogenicity occurs.
However a clinician might wish to induce immunological tolerance.
40% of patients have ADA with infliximab,
Animal models cannot predict immunogenicity.
Thus ADA assays are needed.
![Page 20: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/20.jpg)
Part 3 : Applications
![Page 21: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/21.jpg)
APPLICATIONS OF IMMUNOGENICITY AT MEDIMMUNE
![Page 22: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/22.jpg)
APPLICATION OF IMMUNOGENICITY TO VACCINE DEVELOPMENT : IMMBIO
PBS (c) BCG Boost Vaccine ATP + Cargo
ATP Vaccine Anti-Sera 6 810 Ab (c)885 Ab (c)
Mouse anti-sera generated from TB (Tuberculosis) study.
Show anti-sera detects M. Tuberculosis not cross reactes human cell lysates.1. Hsp70 BCG
Hytest 2. HEK 293 T cells3. CHOs4. SF9 insect5. Mouse
Hperdermal cells (5AF A4 F2)
Tissue culturing, RIPA buffer, SDS-PAGE, Coomassie staining & Western Blot.
![Page 23: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/23.jpg)
APPLICATION OF IMMUNOGENICITY TO GENE THERAPY
Hoechst
eGFP
Calbindin Hoeshst Calbindin eGFP
Hoeshst Calbindin eGFP
Hoeshst Calbindin eGFP
Cathepsin K Inhibitor does not alter lentiviral vector tropism towards Purkinje neurons, even when added a day earlier then lentiviral vectors .
x5 x20
x40
![Page 24: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/24.jpg)
CONCLUSIONS Implementing GLP/GCP at low cost have
meaningful value to MedImmune and science.
Scientists rely on other scientists – It’s in our interests.
Can we trust the data? In the context of human health this is paramount.
Combining these principles in biologic immunogenic capacity ensures better studies, better methodologies, better sciences and better patients.
![Page 25: The challenges of glp gfp in context of immunogenecity assays for biologics - med immune presentation 10-3-2017 eric garson](https://reader031.vdocuments.mx/reader031/viewer/2022021922/58ef5db41a28ab425c8b4569/html5/thumbnails/25.jpg)
ACKNOWLEDGEMENTS AND REFERENCES Claire Entwisle -
Head of Laboratory ImmBio
Professor Gerrit Jan Wolbink
Rachel Ellis MChem CertRP - Account Consultant SRG
MedImmune Talent Acquisition Team
Joanne Goodman MedImmune
Thank you & Any Questions
1. Thorpe et al. Immunological assessment of Biotherapeutic Products: An Overview of Assays and Their Utility. Biologicals. 43. 298-306. 2015.
2. Van Schouwenburg P.A. et al. Immunogenicity of Anti-TNF Biologic Therapies for Rheumatoid Arthritis.. et al. Nature Reviews Rheumatology. 9. 164-172. 2013.
3. K.Bloem et al. Systemic Comparison of Drug Tolerant Assays For Anti-Drug Antibodies in Cohort of Adalimumab-Treated Rheumatoid Arthritis Patients. Journal of Immunological Methods. 11963. 2015.
4. Gunsior. Implications of Immunogenicity in Drug Development. Covance Laboratories. Global Bioanalytical Services White Paper.
5. Hancock, S. Meeting the Challenges of Implementing Good Laboratory Practices in Compliances in a University Setting. Journal of Quality Assurance. 6. 15-21. 2002
6. Goodwin, M. Good Laboratory Practice 30 Years on: Challenges for Industry. Ann 1st Super Santa. 44.4 369-373. 2008.
7. Good Laboratory Practices. Lori Gladney, Lori Gladney, Izabella OsakweI zabella Osakwe, Endia Ford. SlideShare. 2014.
8. http://www.oecd.org/chemicalsafety/testing/goodlaboratorypracticeglp.htm
9. https://globalhealthtrainingcentre.tghn.org/elearning/education/elearning-courses/introduction-to-investigators-responsibilities-with-good-clinical-practice/245/
10. https://www.youtube.com/watch?v=kdEdenHEnlc11. https://www.medimmune.com/